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THE Vps10p-DOMAIN RECEPTOR FAMILY 
Background 
Vps10p-domain (Vps10p-D) receptors are type-I transmembrane proteins sharing 
as a common feature and hallmark an N-terminal Vps10p-D domain, which was 
named after the yeast-sorting protein Vps10p (Vps, for vacuolar protein sorting 
defective). The structure of Vps10p receptor is characterized by a large N-terminal 
luminal moiety and a short cytoplasmic domain. The luminal part contains two 
homologous regions, each characterized by a C-terminal motif of 10 cysteine residues 
(10CC motif), the spacing of which is conserved [1]. The family of mammalian type-I 
transmembrane receptors containing a Vps10p domain comprises five members, 
namely sortilin, SorCS1, SorCS2, SorCS3, and SorLA [2-7]. All of them carry a 
single Vps10p-D situated at the N-terminus of their luminal/extracellular moiety (Fig. 
1). In sortilin, also known as neurotensin receptor-3 [8], the Vps10p-D makes up the 
entire luminal/extracellular part of the receptor, but additional modules are found in 
the other four receptors. In SorLA, the Vps10p-D is followed by 5 low-density 
lipoprotein receptor (LDLR) class B repeats flanked by an EGF precursor-type repeat, 
a cluster of 11 LDLR class A repeats, and 6 fibronectin type-III repeats. Due to the 
presence of the 11 LDLR class A repeats, SorLA was also named LR11 [9]. The 
mutually highly homologous SorCS1, SorCS2, and SorCS3 contain a leucine-rich 
segment between the Vps10p-D and the transmembrane domain. Structure prediction 
of the leucine-rich segment suggests a beta-sandwich fold and relates the domain to 
the E-set superfamily [10]. Following the extracellular and transmembrane segment, 
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each receptor carries a short (40–80 amino acids) cytoplasmic domain comprising 
typical motifs for interaction with cytosolic adaptor molecules.  
 
                         
 
 
 
 
 
 
 
 
Fig.1: Structural organization of the Vps10p-domain receptor family 
 
 
Evolutionary history and gene organization 
Receptors containing a Vps10p-D have been identified in several eukaryotes, but 
not all protein domain combinations are present in all phyla. Mammalian Vps10p-D 
receptor genes are large (up to 600 kb) and span multiple, usually small, exons [7, 
11]. Sequence similarity between the distinct mRNAs and proteins in an individual 
organism is very high for SorCS1 and SorCS3, e.g., 88% overall identity between the 
human mRNAs [12]. Whereas the other Vps10p-D receptor genes are dispersed 
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throughout the genome, SorCS1 and SorCS3 are located adjacent to each other on one 
chromosome, e.g., human chromosome 10q23.3. This indicates that one gene 
originates from the other by gene duplication. Within the receptor family, splice 
variants are known only for SorCS1. The alternative use of composite 
internal/terminal and terminal exons results in different receptor isoforms with 
identical extracellular and transmembrane parts but with different cytoplasmic 
domains [13-15]. The alternative cytoplasmic domains differ in sequence and length 
and present different consensus motifs for interaction with cytosolic adaptor proteins. 
 
Localization 
Analysis of the expression of the Vps10p-D receptors was performed in mice and 
men. In the adult, all receptors are prominently expressed in the nervous system but 
are also found in other tissues and organs [2, 3, 5-7, 9, 12, 16, 17]. During embryonic 
and postnatal development, all five genes are expressed in a dynamic and sometimes 
transient fashion [6, 12, 18-20]. Although the developmental expression of the 
receptors predominates in the nervous system, sortilin is also highly expressed in the 
embryonic lung and SorLA is expressed in several developing glands, such as the 
thyroid gland, and shows a strong expression in the embryonic lung and kidney. In 
addition to the nervous system, in the adult high expression was found for SorLA in 
liver, testis, and kidney, and sortilin is highly expressed in testis and skeletal muscle. 
SorCS1 is expressed in adult liver, kidney, and heart, and SorCS2 expression was 
found in adult lung and testis. 
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Specific structural features 
The aminoacid similarity among all Vps10p-D proteins is relatively limited, but 
two structural features are conserved from yeast to mammals and characterize the 
domain: an N-terminus comprising a consensus motif for processing by proprotein 
convertases (Fig. 1) and a C-terminal segment containing 10 conserved cysteine 
residues (10CC motif).  
Sortilin, SorLA, SorCS1, and SorCS3 are synthesized as precursors and converted 
in the trans-Golgi network to mature receptors by proprotein convertase-mediated 
cleavage and subsequent dissociation of their propeptides [7, 8, 14, 21-24]. The 
Vps10p-D of sortilin and SorLA need the propeptide cleavage to expose their ligand-
binding region. Their propeptides bind to the mature receptors with high affinity and 
inhibit binding of ligands, therefore propeptide cleavage affects sortilin and SorLA 
for ligand binding [22, 23]. The prevention of premature binding of ligands to the 
receptors was suggested as one function of the propeptides [23, 25]. In addition, the 
propeptides may have a chaperone-like function. It has been shown for sortilin that its 
propeptide promotes the transport of the receptor through Golgi compartments but 
seems to be required for receptor folding [25]. However, SorCS1 and SorCS3 do not 
bind their own propeptides and neither SorLA, SorCS1, nor SorCS3 depend on their 
propeptides for transport in the biosynthetic pathway [14, 24, 25]. Therefore it is 
likely that the propeptides have different functions or may be redundant for some of 
the Vps10p-D family members. 
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The C-terminal segment of the Vps10p-Ds is characterized by 10 cysteine 
residues. Exchanging the 10CC module of sortilin and SorLA leads to a 
corresponding change in affinity for receptor-specific ligands [25]. Therefore it was 
suggested that the 10CC module contributes to the binding of specific ligands [25]. 
Based on a computational approach, it was proposed that the N-terminal part of the 
Vps10p-D of sortilin has a beta-propeller fold [26]. Recently, the crystal structure of 
the sortilin Vps10p-D in complex with its ligand neurotensin revealed that the N-
terminal part has indeed a 10-bladed beta propeller structure and is followed by two 
small domains, designated 10CC-a and 10CC-b, which constitute the 10CC module. 
Both have a low content of secondary structure and interact extensively with the beta-
propeller [27]. 
 
Function  
It is well established that in mammalian cells many newly synthesized hydrolytic 
enzymes are targeted to lysosomes by binding to mannose-6-phosphate receptors 
(MPRs). The yeast vacuole is equivalent to the lysosomes of higher eukaryotes. 
Vacuolar protein sorting in yeast and lysosomal protein sorting in mammalian cells 
may share similar mechanisms, but no mannose-6-phosphate-mediated sorting has 
been found in yeast. The established pathway involves the yeast protein Vps10p as a 
sorting receptor [1, 28, 29]. The identification of Vps10p-D receptors in mammals 
caused speculation that these receptors are also capable of mediating sorting of 
ligands from the trans-Golgi network (TGN) to late endosomes or lysosomes [28, 29].  
 - 10 -  
In their short cytoplasmic domains, the Vps10p-D receptors carry typical 
consensus motifs for interaction with cytosolic adaptor proteins, internalization, and 
intracellular sorting. In accordance, sortilin, SorLA, and SorCS1a and c have a 
prominent intracellular vesicular and perinuclear localization [5, 8, 14, 15, 22, 30-32]. 
Surprisingly, SorCS3 predominates on the cellular surface and shows only minor 
intracellular expression [24]. Sortilin, SorLA, SorCS1a, SorCS1c, and SorCS3 can 
also mediate endocytosis [14, 15, 22, 31-33]. 
 
Sortilin 
Sortilin is internalized via clathrin-coated pits, and the identified internalization 
signals are known to facilitate binding to the AP-2 complex [7]. Sortilin delivers 
internalized ligands to lysosomes and transports cargo, from the TGN to endosomes, 
presumably mediated by Golgi-localized, c-adaptin-ear-containing, ADP-ribosylation 
factor-binding proteins (GGAs) [31, 34]. Recent results demonstrate that trafficking 
of sortilin is also facilitated by AP-1, and that the endosome-to-TGN retrieval is 
mediated by the retromer complex [35-38]. The sortilin cytoplasmic domain 
resembles that of MPRs, and sortilin and MPRs colocalize in endosomes and 
endosome-to-TGN carrier vesicles [37]. Furthermore, sortilin conveys lysosomal 
targeting of sphingolipid activator proteins (SAPs), acid sphingomyelinase, and 
cathepsin D and H to lysosomes [36, 39, 40]. Taken together, these data support a 
model of sortilin being an endocytic and intracellular sorting receptor contributing the 
targeting of ligands to lysosomes and the sorting between the Golgi apparatus and 
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endosomes. Therefore, the role of sortilin in Golgi-endosomal trafficking is 
comparable to the function of MPRs.  
Sortilin is expected to serve additional cell- and tissue-specific functions as it is 
expressed in several specialized cell types. For instance, sortilin represents one of the 
major components of glucose transporter isoform 4 (Glut4)-containing vesicles of 
adipocytes and myocytes [41, 42]. In fat and skeletal muscle cells, Glut4 is 
translocated to the cell surface in response to insulin through a system of specialized 
vesicles. In adipocytes, sortilin shows colocalization with Glut4. Moreover, sortilin 
plays an essential role in the formation of Glut4-containing storage vesicles and may 
be involved in the regulation of the insulin-responsive glucose transport system [43, 
44].  
Initially, sortilin was purified by LDL-receptor-associated protein (RAP) affinity 
chromatography [5]. The binding of RAP to the sortilin Vps10p-D is remarkable as it 
appears to be the only RAP-binding receptor structurally not related to the LDL 
receptor family. In addition, binding and internalization of several other, unrelated 
ligands, such as lipoprotein lipase, apolipoprotein A–V, the unprocessed forms of the 
nerve growth factor (proNGF) and brainderived nerve growth factor (proBDNF), and 
the neuropeptide neurotensin was demonstrated [8, 23, 33, 34, 45-47], and several 
findings suggest that sortilin alone or in complex with the G-protein-coupled 
neurotensin receptor-1 may modulate neurotensin signalling [48].  
Sortilin binds the pro-neurotrophins proNGF and proBDNF in concert with the 
neurotrophin receptor p75NTR [45, 46]. The neurotrophins NGF and BDNF promote 
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neuronal survival and growth, but by contrast the unprocessed forms induce cell 
death. Pro-neurotrophins are released by neurons and glia, particularly when cell 
death prevails, for instance, in the developing hypothyroid cerebral cortex, the 
prodromal and end-stages of Alzheimer’s disease, or following brain trauma or 
seizure [49-54]. They form a death receptor complex in which sortilin specifically 
binds the pro-domain of pro-neurotrophins with high affinity, whereas p75NTR 
simultaneously interacts with the mature domain. The formation of this ternary 
complex is crucial for the pro-apoptotic function, as sortilin antagonists rescue 
cultured super cervical ganglion (SCG) neurons from proNGF- and proBDNF-
induced cell death [45, 46]. Sortilin-deficient mice (Sortilin-/- mice) are born viable 
and show no gross abnormalities [51]. Neurons from Sortilin-/- mice are resistant to 
pro-neurotrophin-induced apoptosis. In the developing retina, these mice show 
reduced neuronal apoptosis indistinguishable from p75NTR-deficient mice. Although 
sortilin deficiency does not affect developmentally regulated apoptosis of sympathetic 
neurons, it prevents their age-dependent degeneration. Furthermore lesioned motor 
neurons from sortilin-/- mice are protected from cell death [51]. In agreement, the 
release of recombinant sortilin ectodomain at injury sites reduces death of axotomized 
sensory neurons to the same degree as neutralizing antibodies against the BDNF 
prodomain [55]. Thus, the formation of the ternary complex consisting of pro-
neurotrophin, sortilin, and p75NTR triggers apoptotic signalling under pathological 
conditions, as well as in specific stages of neuronal development and aging. In 
conclusion, sortilin serves not only as a general intracellular sorting receptor, it also 
 - 13 -  
mediates specialized functions, for instance as a co-receptor determining a specific 
signalling pathway. 
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THYROGLOBULIN 
Structure, synthesis and secretion 
Thyroglobulin (Tg) is a 660-kDa glycoprotein composed of two identical 330-kDa 
subunits (monomers) [56]. Complete sequences of human, bovine, mouse and rat Tg 
cDNA have been obtained [57-60]. The 8.5-kb human Tg gene is located on the long 
arm of chromosome 8 and encodes 2,767 amino acid residues, representing the Tg 
monomer [56, 57, 61]. Transcription of the Tg gene requires a complex interplay of at 
least three transcription factors (TTF1, TTF2, and Pax 8), which are also involved in 
transcription of thyroperoxidase (TPO) and of the thyroid sodium/iodide symporter 
(NIS) genes [62, 63]. The thyroid-stimulating hormone (TSH) up-regulates Tg 
synthesis by acting directly on the Tg promoter and indirectly through the thyroid 
transcription factors [56, 62]. Tg is produced exclusively by thyrocytes and follows 
the usual biosynthetic pathway. It is synthesized and initially processed in the 
endoplasmic reticulum with the formation of dimers and with addition of N-linked 
glycoside residues, and then is further processed in the Golgi apparatus, especially by 
modification of carbohydrate residues [64, 65]. Tg is transported via vesicles from the 
trans-Golgi network to the apical surface of thyrocytes, where it is released into the 
lumen of thyroid follicles and stored as the major protein component of colloid 
(>95%) [56]. There is evidence that secretion of Tg is a regulated process rather than 
a constitutive process [56, 66]. This may be useful in achieving a balance between 
release and uptake of Tg, which, under normal conditions, must be equal. Formation 
of thyroid hormone residues within the Tg molecule occurs at the cell-colloid 
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interface by coupling of tyrosyl residues of Tg with iodide, a process that is carried 
out by TPO and other additional enzymes. Five hormonogenic sites have been 
identified in human Tg [56], and it has been estimated that, under physiological 
conditions, a Tg molecule contains on average 2.28 molecules of thyroxine (T4) and 
0.29 molecules of triiodothyronine (T3) [67]. However, the degree of hormone 
content varies among different Tg molecules [56, 67], and Tg molecules that are poor 
in iodide and hormone content are usually referred to as immature. Tg molecules 
within the colloid also differ with respect to the extent and type of glycosylation, and 
there is a correlation between the iodine content of Tg and the nature of its complex 
carbohydrate residues [56, 68]. Because newly secreted Tg molecules are soluble and 
adjacent to the apical surface of thyrocytes, they are the first available for uptake by 
thyrocytes [69, 70]. Newly secreted molecules that escape uptake proceed into the 
colloid, where they undergo further modifications, characterized in part by the 
formation of highly concentrated (up to 750 mg/ml), insoluble, covalently cross-
linked, multimerized forms [70, 71]. Thus, most of the Tg in the colloid is in storage, 
to be solubilized and taken up by thyrocytes only under special circumstances, such as 
iodine deprivation or intense TSH stimulation.  
 
Trafficking 
Tg is the precursor of thyroid hormones and its intrathyroidal metabolism is 
central in thyroid hormone synthesis and secretion. Although some pathways of Tg 
trafficking in thyroid epithelial cells have been characterized, other probably remain 
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to be elucidated, and likely their understanding may be useful for providing the 
molecular basis, and possibly the cure, for several, yet unexplained, forms of 
dyshormonogenetic hypothyroidism.  
 
MICROPINOCYTOSIS AND LYSOSOMAL DEGRADATION 
Hormone release requires degradation of hormone-rich Tg molecules. To some 
extent, Tg degradation and release of T4, but not of T3, can take place within the 
follicle lumen through the action of extracellular proteases located at the apical 
surface of thyrocytes [70]. However, the main pathway of hormone release is 
lysosomal degradation, which occurs following micropinocytosis of Tg by thyroid 
epithelial cells. In rodents, thyroid epithelial cells can internalize Tg by 
macropinocytosis, but in most species, including humans, uptake of Tg occurs mainly 
by micropinocytosis [70, 72]. The majority of investigators agree that fluid phase 
micropinocytosis is the major route of uptake leading to hormone release, because of 
the very high concentrations of Tg within the colloid [70, 72]. Both forms of 
micropinocytosis involve the formation of small vesicles at the plasma membrane 
which invaginate to form intracellular vesicles that fuse with endosomes [70, 72], 
which in turn fuse with lysosome. 
 
ENDOCYTOSIS AND OTHER PATHWAYS OF TG TRAFFICKING 
Interactions between Tg and endocytic receptors on the apical membrane of thyroid 
epithelial cells result in Tg uptake and delivery to post-endocytic pathways. Several 
receptors have been postulated or demonstrated to mediate Tg endocytosis and some 
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are involved in thyroid homeostasis. Because endocytic receptors take up substances 
that are present in very low concentrations in extracellular fluids, it is unlikely that 
they mediate uptake of large amounts of Tg [70, 72]. Receptor-mediated endocytosis 
involves specific binding of certain ligands to cell surface receptors, often with high 
affinity, with the result that even minor components of the extracellular fluid can be 
internalized in large amounts [73]. Receptors may contribute to hormone release 
under special circumstances, for example iodine deficiency, but under physiological 
conditions they are more likely to sort Tg molecules to post-endocytic pathways that 
do not lead to hormone release, namely recycling or transcytosis [72]. The 
contribution of the various means of endocytosis depends on the biochemical features 
of Tg, especially hormone content and degree of glycosylation (Fig. 2). Ultimately, 
both fluid phase endocytosis and receptor mediated endocytosis are aimed at the same 
goal, namely to render hormone release effective, which is achieved not only by 
targeting of Tg to lysosomes, but also by favoring complete glycosylation of 
immature Tg molecules through their recycling, or by eliminating hormone-poor Tg 
molecules from the colloid by transcytosis. The latter process is probably especially 
important when hormone-poor Tg molecules are present in excess within the colloid.  
 
Tg endocytic receptors  
Several molecules expressed on the membrane of thyroid ephitelial cells have been 
proposed to function as Tg endocytic receptors. Two of them, the asialoglycoprotein 
receptor (AGR) and megalin, are well characterized receptors. The characteristics of 
another receptor that binds to exposed N-acetylglucosamine residues of Tg [N-
 - 18 -  
acetylglucosamine receptor (NAGR)] are unknown. As detailed below, the three 
identified Tg receptors probably deliver Tg to different, post-endocytic pathways (Fig. 
2). It is likely that other receptors for Tg also exist [72], but their nature and roles are 
not established. 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   Fig.2: Schematic representation of the known Tg endocytic pathways and of the receptors involved.     
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THE THYROID AGR  
The existence of a thyroid AGR similar to the liver receptor was postulated because 
removal of sialic acid units from Tg increases its binding to thyroid membranes [74]. 
Indeed, AGR is expressed by thyroid ephitelial cells and expression of AGR in 
thyroid PC C13 cells is TSH-dependent [75-77], suggesting a thyroid-specific 
function of the receptor. By immunohistochemistry, AGR can be found on the apical 
membrane of TEC in rat thyroid sections [76], directly facing the follicular lumen, 
therefore in the ideal position to mediate Tg endocytosis.  
Asialo-Tg binds to AGR in solid phase assays and it also binds to the native receptor 
in PC C13 cells [75-77]. In addition, Tg uptake by PC C13 cells can be in part 
reduced by an antibody against AGR [77], suggesting that, at least in cultured cells, 
AGR is involved in Tg endocytosis.  
AGR binds especially to Tg molecules with a low degree of glycosylation, a feature 
that makes it an ideal candidate to be involved in Tg recycling. In addition, other 
studies showed that binding of asialo-Tg to thyroid membranes occurs optimally at 
low pH [74], which should prevent dissociation of Tg from the receptor due to the 
acidic pH of endosomes, as it sometimes occurs in ligand recycling or transcytosis. 
Nevertheless, degradation of Tg in PC C13 cells is reduced by an antibody against 
AGR [77], suggesting that, at least in part, AGR delivers Tg to lysosomes, which 
presumably should result in hormone release. It is possible that, also in view of its 
TSH dependence, AGR may facilitate maximal hormone release under special 
circumstances, for example iodine deficiency. However, a dual role with AGR 
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mediating to some extent also Tg recycling cannot be completely excluded (Fig. 2). 
Unfortunately, no in vivo data are available, and therefore the actual impact of AGR 
on thyroid function remains to be elucidated.  
 
NAGR 
Asialo-agalacto-Tg, obtained by digestion of asialo-Tg with galactosidase, bears 
exposed N-acetylglucosamine residues and it binds to thyroid membranes to a greater 
extent than undigested Tg [78]. In addition, asialo-agalacto-bovine serum albumin 
(BSA) binds to thyroid membranes with high affinity (saturation point 13 nM), and 
binding can be inhibited by unlabeled native Tg and to an even greater extent by 
asialo-Tg and asialo-agalacto-Tg [79]. These findings suggest the existence of a 
NAGR capable of interacting with Tg, which may be responsible for recycling of 
poorly glycosylated Tg molecules (Fig. 2). In support of this, asialo-agalacto-BSA is 
released undegraded following endocytosis by cultured TEC, and ovomucoid, a 
glycoprotein with exposed N-acetylglucosamine residues, accumulates in the Golgi 
following endocytosis by cultured TEC [80]. Although NAGR is very likely to 
mediate recycling, the exact identity of the receptor is unknown, as previous attempts 
to identify it failed. In addition, because studies in vivo are not available, the impact 
of NAGR on thyroid function remains to be established. 
 
MEGALIN 
Megalin is a member of the low density lipoptotein (LDL)-receptor family expressed 
by a restricted group of absorptive cells, including thyroid ephitelial cells, where it 
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can be found on the apical surface [72], thus in the ideal position to mediate Tg 
endocytosis. Megalin expression in thyroid ephitelial cells is up-regulated by TSH 
[72, 81], suggesting a thyroid-specific function.  
Tg binds to purified megalin with high affinity (Kd ~9-11 nM), both in solid phase 
assays and to the native receptor in FRTL-5 cells [81]. In the latter, megalin 
competitors reduce Tg uptake by ~50% [81], suggesting the receptor is involved in Tg 
endocytosis. In most instances, megalin-mediated uptake of ligands results in their 
delivery to lysosomes [81]. However, certain ligands undergo a different intracellular 
fate, namely transcytosis, which is the case for Tg, representing one of the 
mechanisms by which Tg enters the bloodstream. Thus, transport of Tg across   
FRTL-5 cell layers is reduced by megalin competitors [72, 81], and portions of the 
megalin ectodomain (secretory components) remain complexed with transcytosed Tg 
[82]. Furthermore, in conditions associated with increased megalin expression, due to 
TSH (hypothyroid rats) or TSH-like (patients with Graves’ disease) stimulation, a 
relatively high proportion of serum Tg is complexed with megalin secretory 
components [82] and serum Tg levels in megalin KO mice are reduced [83].  
The molecular mechanisms responsible for targeting of the Tg-megalin complex to 
transcytosis are known only in part [84]. Although binding of Tg to megalin is 
optimal at low pH, transcytosis is only minimally affected by increasing intracellular 
pH, suggesting that pH resistance is not a major factor [85]. The calcium-calmodulin 
pathway and phosphoinositide 3-kinase (PI3-K) affect Tg transcytosis. Calmodulin 
antagonists reduce transcytosis and increase T3 release, indicating calmodulin favors 
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transcytosis prior to Tg sorting [81]. In contrast, a PI3-K inhibitor increases Tg 
transcytosis but does not affect T3 release, suggesting that PI3-K exerts an inhibitory 
effect at a post-sorting stage [86]. 
A major role in determining targeting of Tg to transcytosis is related to the ability of 
Tg to bind to cell surface heparinoids. As other megalin ligands, Tg is a heparin-
binding protein and heparin and megalin binding sites are functionally related [81]. 
Occupation of a major heparin-binding sequence of rat Tg (2489-2503) abolishes Tg 
binding to megalin. In addition, transcytosis of rat Tg in FRTL-5 cells is reduced by 
enzymatic removal of cell surface heparan sulfate proteoglycans (HSPGs) as well as 
by an antibody against Tg2489-2503 [83]. In this regard, optimal exposure of 
Tg2489-2503 is crucial, and a greater exposure of Tg2489-2503 in hormone-poor rat 
Tg is responsible for its preferential transcytosis compared with hormone-rich Tg 
[83]. The role of Tg binding to heparinoids appears to be more important in rodents 
than in humans, because Tg2489-2583 is identical in mice and rats, but differs in 
humans by 6 residues, resulting in a weaker Tg binding to heparin [87].  
As mentioned above, transcytosis is preferential for hormone-poor Tg molecules. 
Thus, Tg transport across FRTL-5 cells is greater for hormone-poor than for 
hormone-rich Tg [83]. In addition, megalin-mediated transcytosis in vivo, estimated 
by the proportion of serum Tg complexed with megalin secretory components, is 
enhanced by inhibition of hormone formation within Tg due to thionamide treatment 
[83]. This selective mode of transcytosis renders hormone release more effective, by 
preventing hormone-poor Tg to enter the lysosomal pathway, thereby avoiding 
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competition with hormone-rich Tg, as well as wasteful transcytosis of hormone-rich 
Tg. Thus, megalin KO mice are hypothyroid [88]. Whether megalin deficiency exists 
in humans and it causes thyroid dysfunction remains to be established. 
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Sortilin is a 100 kDa member of the recently discovered family of Vps10p 
domain proteins, which comprises also SorLA ( 250 kDa) and SorCS 1, 2 and 3 (
130 kDa). The hallmark of the family is a Vps10p domain at the N-terminus, which in 
sortilin makes up the entire luminal receptor. In addition to the Vps10p ectodomain, 
the structure of Vps10p proteins is characterized by a transmembrane segment and a 
short cytoplasmic tail, where motifs for interaction with cytosolic adaptor molecules 
are present. Functional sorting sites, namely dileucines, acidic clusters and tyrosine-
based motifs, which are known to be involved in endocytosis and intracellular 
trafficking, have been established in all Vps10p members. The structural 
heterogeneity of the cytoplasmic tail suggests differential and/or alternative functions 
of Vps10p proteins, which is being progressively unveiled especially in the case of 
sortilin. Thus, sortilin is capable of mediating endocytosis of ligands if expressed on 
the cell membrane, but it can also transport proteins from the Golgi to late endosomes 
when expressed in the Golgi, its most abundant and usual location. 
Sortilin shares at least two ligands with the LDL receptor family member megalin, 
namely lipoprotein lipase (LPL) and the receptor associated protein (RAP). In the 
thyroid, megalin serves as a high affinity endocytic receptor for thyroglobulin (Tg), 
which led us to the hypothesis that, because of similarities between sortilin and 
megalin, Tg may be a sortilin ligand. The relevance of the issue stems from the fact 
that although some pathways of Tg trafficking in thyroid epithelial cells (thyrocytes) 
have been characterized, other probably remain to be elucidated, and likely their 
understanding may be useful for providing the molecular basis, and possibly the cure, 
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for several, yet unexplained, forms of dyshormonogenetic hypothyroidism. Thus, Tg 
is the precursor of thyroid hormones and its intrathyroidal metabolism is central in 
thyroid hormone synthesis and secretion. Briefly, Tg is synthesized by thyroid 
epithelial cells and then secreted into the lumen of thyroid follicles, where it 
undergoes hormone formation by coupling of its tyrosyl residues with iodide. 
Hormone-rich Tg molecules can either proceed further into the follicle, where they 
arrange into aggregates that form the colloid, or they can undergo proteolytic 
cleavage, resulting in hormone release[70]. To some extent, Tg degradation can take 
place within the follicle lumen through the action of extracellular proteases, but the 
main route of hormone release is lysosomal degradation, which occurs following 
micropinocytosis of Tg by thyroid epithelial cells. It is generally believed that fluid 
phase-mediated uptake is the main route of Tg micropinocytosis leading to lysosomal 
degradation and hormone release, but endocytic receptors for Tg located at the apical 
membrane of thyroid epithelial cells also exist and some of them have been 
characterized. In most instances, Tg internalized by endocytic receptors is thought to 
undergo intracellular fates other than lysosomal degradation, either recycling  or 
transcytosis. In the recycling pathway, internalized Tg molecules are transported to 
the Golgi and then re-secreted back into the colloid. The responsible receptor has not 
been identified, and the process is thought to serve for poorly glycosilated Tg 
molecules to undergo completion of glycosylation within the Golgi. Transcytosis, a 
route through which Tg is transported intact from the follicle lumen to the 
bloodstream, is mediated by megalin and involves preferentially hormone-poor Tg 
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molecules. By preventing hormone-poor Tg to enter the lysosomal pathway and 
compete with hormone-rich Tg for degradation, transcytosis renders hormone release 
more effective. It is unknown how targeting of Tg towards the various intracellular 
post-endocytic pathways occurs and which molecules are involved.  
The aim of the present thesis was: 
− study the expression of sortilin in thyroid epithelial cells; 
− investigate the interaction between sortilin and the thyroid hormone precursor, 
thyroglobulin;  
− study the role of sortilin-Tg interaction in thyroid homeostasis and the function of 
sortilin in the thyroid gland. 
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Materials 
rTg was purified from frozen rat thyroid glands (Pel-Freeze Biologicals, Rogers, 
ARK); hTg was purified from thyroid glands obtained at surgery from patients with 
Graves’ disease, upon signed informed consent; 5Tg was purified from FRTL-5 cell 
supernatants, as described. hTg was labeled with 125I-Na (Perkin Elmer, Waltham, 
MA) using IODO beads (Pierce, Rockford, IL) (specific activity: 1,500-7,000 
cpm/ng). Tg was labeled with biotin using EZ-Link Sulfo-NHS-LC-Biotin (Pierce). 
hTg was labeled with 20 nm gold particles as described [89]. The content in T3 of the 
three Tg preparations was measured using a competitive T3 assay from MP 
Biomedicals (Orangeburg, NY). Briefly, 25 µg of Tg were diluted in Tg, T3 and T4-
free human serum, collected from thyroidectomized and radioiodine-ablated patients 
upon signed informed consent. Samples were added to anti-mouse IgG coated wells 
together with HRP-conjugated T3 and a mouse anti-T3 antibody. The content of T3 was 
estimated based on a T3 standard curve and it was expressed as Mol/Mol of Tg. 
The extracellular domain of sortilin (s-sortilin) was purified as described [90]. 
Two rabbit polyclonal antibodies against sortilin, one against the luminal part 
(Vps10p-domain) and one against the sortilin tail were described previously [23]. A 
mouse monoclonal antibody against sortilin was generated by immunization of mice 
with the purified sortilin-Vps10p domain. Soluble sorCS3 was purified as described 
[24]. RAP was purified as described [91]. Normal goat and swine sera, neurotensin, 
unlabeled or biotin-labeled BSA, normal rabbit IgG (rIgG) and p-Nitrophenyl-
phosphate were from Sigma (Sigma, St. Louis, MO). A rabbit anti-Tg antibody was 
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from Axell (Westbury, NY). A mouse anti-Tg antibody, either unlabeled or labeled 
with biotin, was from Dako Corporation, (Carpinteria, CA). Rabbit anti-GAPDH and 
FITC-labeled anti-rabbit IgG were from Santa Cruz (Santa Cruz,CA). Biotin-labeled 
swine anti-rabbit IgG was from Dako Corporation. TRITC-labeled streptavidin was 
from Pierce. Texas red-conjugated anti-rabbit IgG was from AbCam (Cambridge, 
UK). HRP-conjugated anti-rabbit and anti-mouse IgG were from BioRad (Hercules, 
CA). Alkaline phosphatase (ALP) conjugated streptavidin was from Amersham 
(Freiburg, Germany). HRP-streptavidin was from Dakopatts (Glostrup, Denmark) and 
from Amersham. Normal human thyroid tissue samples were obtained at surgery from 
the contralateral normal thyroid lobe of six patients who underwent total 
thyroidectomy for differentiated thyroid cancer upon signed informed consent. Rat 
brain and testicles were obtained from Pel-Freeze Biologicals. 
 
Experimental animals and related procedures 
Twelve eight week old C57Bl6 female mice were from Jackson Laboratories (Bar 
Harbor, ME). Six mice received 0.05% methimazole (C4H6N2S, Sigma,) and 0.5% 
sodium perchlorate (NaClO4, Sigma) in drinking water for five days, as described 
previously [92]. Six mice were untreated. Prior to sacrifice, blood samples were 
collected. Sera were stored at -20°C until use. Mice were sacrificed and the thyroid 
glands were harvested and either stored at -80°C for preparation of tissue extracts, or 
fixed in paraformaldehyde, dehydrated and embedded in paraffin for histological and 
immunohistochemical studies. Animal care, treatment and sacrifice procedures were 
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in accordance with institutional guidelines. Animal studies were approved by the 
local review board. 
 
Histology and Immunohistochemistry 
Five µm sections from paraffin embedded specimens were deparaffinized, 
rehydrated and either subjected to standard hematoxylin and eosin (H & E) staining, 
or to immunohistochemistry, using a previously described procedure [93]. Briefly, 
sections were incubated with 3% H2O2, microwaved with antigenic unmasker (MS-
UNMASKER 30PA-0285, Diapath, Bergamo, Italy), and blocked with normal swine 
serum (Sigma). Sections were incubated overnight at 4°C with rabbit anti-sortilin 
(130 µg/ml in PBS containing 0.1% BSA) or rabbit anti-Tg (1:100). Sections were 
washed with PBS, and then incubated with biotin-labeled anti-rabbit IgG, followed by 
HRP-conjugated streptavidin and 3,3’-diaminobenzidine tetra-hydrochloride. Sections 
were counterstained with hematoxylin.  
 
Preparation of tissue extracts 
Tissue samples were washed, minced and homogenized. Samples were incubated 
in lysis buffer [50 mM Tris pH 8.6, 0.5 M NaCl, 10% Triton X-100, 0.01% 
deoxycholate, 20 mM EDTA, 0.2% NaN3 and 10% protease inhibitor cocktail 
solution (Roche Diagnostics, Mannehim, Germany)] and spun for 30 minutes at 
10,000 x g. Supernatants, were collected and briefly sonicated. Protein concentrations 
was measured with the Bradford method.  
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Serum assays in mice 
FT4 was measured by equilibrium dialysis immunoassay (Nichols, San Juan 
Capistrano, CA). Serum TSH was kindly measured by Dr. Samuel Refetoff, 
Departments of Medicine and Pediatrics, University of Chicago, with a previously 
described radioimmunoassay [94]. 
 
Cell cultures and related  procedures 
      FRTL-5 cells (American Type Culture Collection. Rockville, MD) were cultured 
as described [95], in Coon's F12 medium containing 5% newborn calf serum and a 
mixture of five hormones plus bovine TSH (Sigma) 1 mU/ml. In certain experiments, 
cells were cultured for 24-72 hours either in medium lacking TSH, or in medium 
containing TSH at various concentrations. FRTL-5 cells were membrane-labeled with 
EZ-Link Sulfo-NHS-LC-Biotin according to the manufacturer’s instructions.  In 
certain experiments, sortilin in FRTL-5 cells was silenced by transient transfection 
with the following sense mRNA sequence: 5’-
CCCGUCUACUUCACCGGGCUGGCUU-3’. The following scrambled sortilin 
sequence was used as a control: 5’-CCCUCCAUUACCCGGCGGUGUGCUU-3’. 
Transfections were performed using Lipofectamine 2000 (Invitrogen, Carlsband, CA). 
Expression of sortilin after transfection was determined by RT-PCR as follows. RNA 
samples were isolated using the Trizol reagent (Invitrogen). Single-stranded cDNA 
was synthesized from 1 µg of total RNA using the SuperScript First-Strand Synthesis 
System (Invitrogen) for RT-PCR. The following PCR primers were designed with 
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Primer3 software21 [96]: forward: CAGACAGACCTCCCCTTTCA; reverse:  
AATTCTTGGACACCCACAGG. PCR was performed with SYBR® Green PCR 
Master Mix (Applied Biosystems, Foster City, CA). The reaction conditions were: 
two minutes at 50°C (1 cycle), 10 minutes at 95°C (1 cycle), 15 seconds at 95°C and 
one minute at 60°C (50 cycles). Gene-specific PCR products were continuosly 
measured with the ABI PRISM 7900 sequence detection system (Applied 
Biosystems). Samples were normalized using a housekeeping gene (β-actin). Sortilin 
protein was measured in cell extracts by Western blotting as reported below.  
COS-7 cells (American Type Culture Collection) were cultured in Dulbecco’s 
modified Eagle’s medium containing 10% fetal bovine serum. COS-7 cells were 
transiently transfected using the diethylaminoethyl-dextran method [97] with either 
one or more of the following cDNAs: i) a previously described full length sortilin 
cDNA cloned into a pcDNA3 expression vector [23] and ii) a previously described 
[98] bovine Tg cDNA, cloned into a pCB6 expression vector, kindly provided by Dr. 
Peter Arvan, (Division of Metabolism, Endocrinology and Diabetes, University of 
Michigan, Ann Arbor, MI). For co-transfection experiments we used the following 
control cDNAs: human MC4, cloned into a pcDNA3 expression vector [99]. In 
certain experiments in which COS-7 cells had been transfected with Tg cDNA or co-
transfected with Tg plus sortilin cDNAs, following transfection, cells were cultured 
for 48 hours in medium containing Tg-free human serum in place of fetal bovine 
serum. Then, supernatants were collected and cell extracts were prepared for Tg 
detection by Western blotting.  
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CHO cells (American Type Culture Collection) were cultured in Ham’s F12 
medium containing 10% fetal bovine serum.  CHO cells were stably transfected with 
full length sortilin cDNA using Lipofectamine 2000. 
 
Preparation of cell extracts 
Cells were detached from plates with 0.5 mM EDTA in PBS, washed with PBS, 
and incubated on ice for one hour in lysis buffer (1% Triton X-100, 1% deoxycholate 
in H2O). Samples were spun for 10 minutes at 10,000 x g, the pellets were discarded 
and the supernatants were collected. Protein concentrations were measured with the 
Bradford method. 
 
Immunofluorescence Staining 
FTRL-5 cells were cultured on glass cover slips and fixed. Before fixation, in 
certain experiments cells were incubated at 37°C with biotin-labeled hTg (100 µg/ml 
in serum-free cell medium containing 5 mM CaCl2, 0.5 mM MgCl2 and 0.5% BSA). 
Cells were washed with PBS, fixed with 4% formaldehyde, permeabilized with 0.2% 
Triton X-100 in PBS, and blocked with PBS containing either 5% serum (either goat 
or donkey), 5% BSA and 0.1% Tween-20. Cells were incubated at room temperature 
for 2-16 hours with 5% goat  serum, 5% BSA and 0.1% Tween-20 in PBS, containing 
either one of the following antibodies or antibody combinations: i) mouse anti-sortilin 
(20 µg/ml); ii) rabbit anti-sortilin (0.88 or 4.4 mg/ml) and iii) mouse anti-Tg (1:400). 
Cells were washed three times with PBS containing 0.1% Tween-20, and once with 
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PBS alone and then incubated for one hour at room temperature with either one or 
with a combination of the following secondary antibodies, depending on the primary 
antibodies used: i) FITC-labeled anti-rabbit IgG (diluted 1:500); ii) TRICT-labeled 
anti-mouse IgG (1:100) and iii) Texas red-labeled anti-rabbit IgG (1:200). In 
experiments in which biotin-labeled Tg was used, the second incubation was 
performed with TRITC-labeled streptavidin (1:2000) alone, or, in experiments in 
which the anti-Tg antibody was added with rabbit anti-sortilin, together with FITC-
labeled anti-rabbit IgG. Cells incubated with secondary antibodies or streptavidin 
alone were used as negative controls. After the second incubation cells were washed 
as reported above. Nuclei were counterstained with the nuclear marker DAPI (Santa 
Cruz). After completion of all incubation steps, cells were extensively and rapidly 
washed with H2O and finally mounted on glass slides. Staining was assessed using an 
Eclipse 80i fluorescence microscope (Nikon, Chiyoda-ku, Tokyo, Japan). 
 
Immunolectronmicroscopy 
FRTL-5 cells were cultured until confluence on high density large pore (3 µm) 
filters in cell culture inserts (Becton Dickinson, Mountain View, CA). In certain 
experiments cells were incubated at 37°C with gold-labeled Tg (50 µg/ml in serum-
free medium containing 5 mM CaCl2, 0.5 mM MgCl2 and 0.5% BSA). Cells were 
fixed with 4% paraformaldehyde, 0.5% glutaraldehyde in 50 mM phosphate buffer 
pH 7.2, rinsed in the same buffer and dehydrated with ethanol. Then, cells were 
embedded in LR white methacrylate resin and gradually raised in absolute ethanol 
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from 30% to 100%. Cells were placed in gelatine and allowed to polymerize in the 
presence of benzoyl peroxide and ultrathin sections were obtained. For immunogold 
staining, cells were blocked with nickel grids. For sortilin staining, sections were then 
incubated with rabbit anti-sortilin (1:1000). Grids were washed and incubated with 10 
nm gold-labeled goat anti-rabbit IgG (British BioCell International, UK). Grids were 
washed and sections were stained with uranyl acetate. Sections were analyzed with a 
Jeol JEM EX II transmission electron microscope (JEOL Ldt, Tokio, Japan). Sections 
incubated with the secondary antibody alone were used as a control. 
 
Immunoprecipitation experiments 
Samples were incubated overnight at 4°C with protein A beads coupled with 
rabbit anti-sortilin (650 µg), or, as a control, with normal rabbit IgG. Beads were spun 
down, washed extensively, and incubated with reducing Laemmli buffer, following 
which beads were spun down again. Supernatants were collected and subjected to 
Western blotting for sortilin or Tg (see below). In certain experiments with cell 
extracts, cells had been pre-incubated with a membrane permeable cross-linker 
[Dithiobis succinimidyl propionate (DSP), Pierce]. 
 
Western blotting 
Samples were subjected to SDS-PAGE and then blotted onto nitrocellulose 
membranes, which were then incubated with either one of the following: i) rabbit 
anti-sortilin (88 to 440 µg/ml) or ii) rabbit anti-GAPDH (1:200), or iii) rabbit anti-Tg 
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(1:2500), followed by HRP-conjugated anti-rabbit IgG (1:3000); iv) mouse anti-
sortilin (2.5 µg/ml) followed by HRP-conjugated anti-mouse IgG (1:3000), or v) 
horseradish peroxidase (HRP)-conjugated streptavidin (1:3000). Bands were detected 
by ECL and their density was measured using ImageJ (National Institute of Health, 
Bethesda, MD). 
 
Biosensor binding assays 
All assays were performed using a BIAcore 3000 instrument (GE Healthcare 
Europe GmbH, Uppsala, Seweden) with CM5 sensor chips maintained at 20°C. The 
sensor surface was under a continuous flow (5 µl/min) of 10 mM HEPES, pH 7.4, 3.0 
mM EDTA, 150 mM NaCl, and 0.005% surfactant P20. The carboxylated dextran 
matrix of flow cells 1–4 was activated by injection of 0.2 M N-ethyl-N-(3-
dimethylaminopropyl)carbodiimide and 0.05 M N-hydroxy-succimide in water (240 
µl). A 10 mM sodium acetate solution (pH 4.0) of 10–30 µg/ml of purified receptor 
(s-Sortilin, s-SorCS3) was then injected over flow cells 2–4 at 5 µl/min, and the 
remaining binding sites in all four flow cells were subsequently blocked by injection 
of 1 M ethanolamine, pH 8.5. The amount of immobilized protein, as determined by 
the relative response, varied between 60 and 80 fMol/mm2. Binding of the three Tg 
preparations was determined by injecting 40-µl aliquots (0.01–5 µM ligand, 5 µl/min) 
through all flow cells, either alone or in the presence of competitors (RAP, 
neurotensin). Unless otherwise stated, the samples were dissolved in 10 mM HEPES, 
pH 7.4, 150 mM NaCl, 1.5 mM CaCl2, 1 mM EGTA, 0.005% surfactant P20, which 
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was also used as running buffer. The surface plasmon resonance signal was expressed 
in relative response units; i.e. the difference in response between the immobilized 
protein flow cell and the corresponding control flow cell (i.e. flow cell 1, activated 
and blocked but without protein). Regeneration of the sensor chip after each cycle of 
analysis was performed with 10 mM glycine/HCl, pH 4.0, 500 mM NaCl, 20 mM 
EDTA, and 0.005% surfactant P20. The BIAevaluation 3.1 software was used to 
determine kinetic parameters. 
 
Cell binding, uptake, degradation, recycling and transcytosis assays 
 In binding and uptake assays with biotin-labeled ligands, cells were cultured in 24 
well plates until 80-100% confluence. In binding assays cells were pre-incubated for 1 
h at 4°C with BSA 1 mg/ml in binding buffer (serum-free medium containing 5 mM 
CaCl2, 0.5 mM MgCl2 and 0.5% BSA). Then cells were incubated for 1 hour at 4°C 
with various concentrations of biotin-labeled hTg or BSA, following which cells were 
washed with serum free medium and incubated for 1 hour at 4°C with 0.5 M NaCl in 
PBS to detach bound proteins from membranes. The NaCl wash was collected and 
bound biotin-labeled proteins were measured by ELISA. In uptake assays cells were 
incubated for various time points at 37°C with various concentrations of biotin-
labeled Tg or BSA. Then, cells were lysed by incubation for one hour with H2O and 
the cell lysate was collected to measure internalized biotin-labeled proteins by ELISA.  
In other experiments, binding, uptake and degradation were measured using 121I-
labeled hTg. Cells were cultured in 24 well plates until 80-100% confluence. Cells 
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were incubated for 6 hours at 37°C with 121I-labeled Tg (40 ng/ml) in 500 µl of 
binding buffer (serum-free medium containing 0.5% ovalbumin). Then, binding 
buffer was collected and subjected to precipitation with trichloroacetic acid (TCA). 
Radioactivity in the TCA non-precipitable material was determined with a gamma 
counter as a measure of Tg degradation. Cells were detached from plates with trypsin 
and spun down. The trypsin wash was collected and radioactivity was determined as a 
measure of membrane binding. The pellet was lysed with lysis buffer and 
radioactivity was determined as a measure of uptake.  
For transcytosis assays, cells were cultured until confluence in high density large pore 
(3 µm) filters in cell culture inserts placed in 24 well plates. Cells on filters were 
incubated at 37°C with unlabeled hTg (35 µg/ml) in Coon's F12 medium, containing 
5 mM CaCl2, 0.5 mM MgCl2, 0.5% BSA. Tg was added to the upper chamber in a 
volume of 300 µl and the lower chamber was rinsed with 400 µl of buffer without Tg. 
After 6 hours the medium from the lower chamber was collected and Tg was 
measured by ELISA. In all cells used for transcytosis experiments, measurement of 
transepithelial resistance as well as measurement of 3H-mannitol passage across the 
layers excluded the presence of significant paracelluar leackage (not shown).  
For recycling assays, cells were cultured in 24 well plates until 80-100% confluence. 
Cells were incubated at 37°C with unlabeled hTg or BSA (250 µg/ml) in binding 
buffer (Coon's F12 medium, 5 mM CaCl2, 0.5mM MgCl2, 0.5% BSA), to allow 
internalization. After 2 hours cells were washed with ice cold binding buffer and 
 - 40 -  
incubated for 2 hours at 37°C with binding buffer to allow release of internalized Tg, 
which was measured by ELISA. 
Results of all experiments were normalized for the amount of proteins in cell extracts, 
which was measured in cell lysates with the Bradford method. 
 
ELISA 
To measure biotin-labeled proteins, 96 well microtiter plates were coated 
overnight at 4°C with samples and then blocked for 3 hours at 4°C with 1 mg/ml of 
BSA. Wells were incubated for 1 h at room temperature with ALP-conjugated 
streptavidin (1:4000 in PBS containing 0.05% Tween-20 and 0.5% BSA), followed 
by p-Nitrophenyl-phosphate. Absorbance was determined at 405 nM. The amounts of 
biotin-labeled proteins were estimated using standard curves obtained by coating 
microtiter wells with biotin-labeled Tg or BSA. To measure unlabeled Tg, wells 
coated overnight at 4°C with samples to be tested were incubated with rabbit anti-Tg 
(1:500) followed by ALP-conjugated anti-rabbit IgG and p-Nitrophenyl-phosphate. 
The amounts of Tg were determined using a standard curve obtained by coating 
microtiter wells with unlabeled hTg. 
 
Data presentation and statistics 
Experiments with mouse tissue sections, extracts and sera were performed in at 
least 6 mouse pairs. All the remaining experiments were performed at least 3 times. In 
all experiments either the same sample volumes or the same amount of protein 
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extracts were used for comparisons. When appropriate, statistical analyses by Mann 
Whitney were performed using Stat-View (SAS Institute Inc, Cary, NC). Unless 
otherwise specified, results are presented as mean±SD. 
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Expression of sortilin in thyroid epithelial cells 
We investigated expression of sortilin in thyroid epithelial cells, using thyroid 
tissue and FRTL-5 cells, a differentiated rat thyroid cell line . As shown in Fig. 3a 
(upper panel), sortilin was detected by immunohistochemistry in mouse thyroid 
sections. Staining was observed exclusively within the cytoplasm of thyroid epithelial 
cells, being in some cells spotted more intensely in the perinuclear area. No clear 
membrane staining was seen. Staining for sortilin was distinct from Tg staining (Fig. 
3a, lower panel), which was mainly concentrated in the extracellular compartment, 
namely in the follicle lumen, although in isolated cells there was some intracellular 
staining representing either nascent or endocytosed Tg molecules. 
Sortilin was found to be expressed by FRTL-5 cells under standard culture 
conditions, namely in medium containing TSH 1 mU/ml (Fig. 3b), and staining was 
observed exclusively intracellularly. Immunolectronmicroscopy in cells cultured on 
permeable filters confirmed an exclusive intracellular localization of sortilin (Fig. 3c). 
Thus, sortilin was seen especially in cytoplasmic vesicles, in the proximity of both the 
lower (Fig. 3c left panel) and the upper membrane (Fig. 3c right panel).  
As shown in Fig. 3d, bands immunoreactive with an anti-sortilin antibody were 
observed in human, mouse and rat thyroid extracts, as well as in extracts from   
FRTL-5 cells. These bands migrated at ~100 kDa, the known molecular mass of 
sortilin . Bands of similar mass were revealed by anti-sortilin antibodies in positive 
control tissues, namely rat brain or testicle (Fig. 3d). Although sortilin migrated as a 
single band in mouse and human thyroid and in FRTL-5 extracts, as it did in the rat 
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brain, it resolved into two separate bands in rat thyroid extracts, as it did in the rat 
testicle. In addition, the sortilin band was slightly slower in human thyroid extracts. 
Presumably, the findings reflect either the presence of differently glycosylated forms 
of sortilin, thereby resulting in two separate bands, or a different degree of 
glycosylation of sortilin, thereby resulting in a slower band.  
As reported above, immunostaining experiments showed that in thyroid epithelial 
cells sortilin is not expressed on the cell membrane. To investigate this issue further, 
FRTL-5 cells were surface-labeled with biotin, following which membranes were 
subjected to immunoprecipitation with anti-sortilin antibodies. As shown in Fig. 3e, 
no biotin-labeled bands were precipitated by the anti-sortilin antibody, confirming 
that expression of sortilin on the cell membrane is virtually absent.  
 
 
 
 
 
. 
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Figure 3  Expression of sortilin in thyroid epithelial cells. a) Sortilin and Tg expression by 
immunohistochemistry in mouse thyroid sections. Sortilin (upper panel) is detected intracellularly (black 
arrows). Tg (lower panel) is mainly concentrated in the follicle lumen (black arrows), but in isolated cells 
intracellular staining is seen (green arrows); b) Immunofluorescence stainings in FRTL-5 cells, using 
polyclonal (upper panel) or monoclonal (lower panel) anti-sortilin antibodies. Sortilin is mainly 
concentrated in the perinuclear area (white arrows); c) Immunoelectronmicroscopy in FRTL-5 cells. 
Sortilin in seen mainly in cytoplasmic vesicles (black arrows), near the upper (left panel) and lower 
membrane (right panel); d) Western blotting for sortilin in thyroid extracts and in extracts from FRTL-5 
cells. Rat brain and testicle extracts were used as positive controls. Arrows indicate the bands 
corresponding to sortilin; e) Immunoprecipitation with anti-sortilin antibodies of FRTL-5 cell extracts 
(lane 1) following membrane labeling with biotin, detected by Western blotting with streptavidin. Rat 
testicle extract (lane 2) was used as a positive control. Arrow indicates the band corresponding to sortilin 
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Expression of sortilin in thyroid epithelial cells is TSH-dependent 
Virtually all proteins involved in thyroid function are regulated by TSH. We 
investigated whether also sortilin undergoes this type of regulation, both in a mouse 
model and in FRTL-5 cells. We first studied the effects of TSH on sortilin expression 
in mice treated with methimazole and sodium perchlorate, which, especially if used in 
combination, are potent inhibitors of thyroid hormone synthesis, leading to 
hypothyroidism and increased TSH secretion from the pituitary, which makes it a 
suitable model to study protein expression in response to TSH. As shown in Fig. 4a, 
following treatment of mice for 5 days, there was a reduction of serum free thyroxine 
(FT4) and a marked increase of serum TSH. The typical morphological and 
histological changes induced by TSH were observed. Gross examination of the 
thyroid gland revealed a slight enlargement and engorgement compared with 
untreated mice (not shown). At histology (Fig. 4b), there was hypertrophy of thyroid 
epithelial cells, reduced amounts of colloid and of the size of follicular lumina, 
indicating massive colloid reabsorption. Staining of thyroid epithelial cells with an 
anti-sortilin antibody was markedly increased in mice treated with methimazole and 
perchlorate compared with untreated mice (Fig. 4c), and similar results were obtained 
by Western blotting analysis of thyroid extracts (Fig. 4d and e). The effects of 
treatment on sortilin was specific, as expression of the housekeeping protein 
glyceraldehydes-3-phosphate-dehydrogenase (GAPDH) was unaffected (not shown), 
as also reported previously [100] . 
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We then investigated the same issue in FRTL-5 cells. Cells were cultured either in 
media containing various concentrations of TSH or in medium lacking TSH, for time 
intervals ranging from 24 to 48 hours. As shown in Fig. 4f-h, TSH up-regulated 
sortilin, as observed both by immunofluorescence staining and Western blotting. The 
effect of TSH was time-dependent, indicating that prolonged stimulation is more 
effective than acute stimulation (Fig. 4 g and h). The effect was seen starting at 
relatively low concentrations of TSH (0.25 mU/ml), and it plateaued at concentrations 
greater than 0.5 mU/ml (Fig. 4 g and h), indicating that the effect was somehow 
saturable, as expected for a receptor/ligand-mediated mechanism, as it should be in 
the case of TSH/TSH-receptor interactions. TSH did not affect expression of GAPDH 
(not shown), as also reported previously , suggesting that its effect on sortilin was 
specific. 
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Figure 4  Expression of sortilin in thyroid epithelial cells is TSH-dependent. a-e) Mice treated 
with methimazole and sodium perchlorate. a) FT4 and TSH serum levels; b) H&E staining of 
thyroid sections; c) Immunohistochemistry for sortilin in thyroid sections. Intracellular staining 
is increased in thyrocytes in mice treated with methimazole and perchlorate; d) Western blotting 
for sortilin in thyroid extracts; e) pixel densities of the bands in Western blotting experiments; f-
h) FRTL-5 cells. f) Immunofluorescence staining with an anti-sortilin antibody in cells cultured 
for 24h in medium lacking TSH or containing TSH 1mU/ml; g) Western blotting for sortilin in 
extracts from cells cultured for different time periods (24-48h) in media containing various 
concentrations of TSH, as indicated; e) Pixel densities of the bands in Western blotting 
experiments. 
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Tg is a sortilin ligand 
We investigated whether Tg is a sortilin ligand, using surface plasmon resonance 
binding assays. For this purpose, we used a purified, soluble preparation of sortilin (s-
sortilin), and three purified Tg preparations, namely rat Tg (rTg), human Tg (hTg), 
and Tg purified from FRTL-5 cell supernatants (5Tg). As shown in Fig. 5a, the three 
preparations had a different hormone [(triiodo-thyronine (T3)] content. Thus, rTg was 
highly hormonogenic, whereas hTg and 5Tg had a lower T3 content. This was 
expected based on the knowledge that rTg was purified from the thyroids of untreated 
rats, that hTg was purified from the thyroids of Graves’ patients given methimazole [a 
potent inhibitor of hormone formation within Tg], and that FRTL-5 cells are not 
capable of forming hormone residues within the Tg molecules they produce. As 
shown in Fig 5b, all of the three Tg preparations bound to immobilized sortilin in a 
concentration-dependent manner and with high affinity, as indicated by the following 
mean Kd values:  rTg: ~1 nM; hTg: ~3 nM; 5Tg: ~30 nM. The apparent different 
extent of binding between the 3 Tg preparation actually reflects the different 
concentrations used (rTg: 25 nM; hTg: 100 nM; 5Tg: 100 nM). No binding to 
sorCSC3, another member of the Vps10p family, was observed (not shown). An 
example of the dose-dependent, high affinity pattern of binding is shown in Fig. 5c 
for hTg. Similar results, with different Kd values, were obtained also for rTg and 5Tg 
(not shown). As shown in Fig. 5d, binding of all the three Tg preparations was 
inhibited, if not abolished, by the sortilin ligand neurotensin. In addition, binding was 
almost abolished by RAP, as shown for hTg in Fig. 5e. Because RAP binds to both 
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sortilin  and Tg, we could not establish to what extent inhibition was due to RAP 
binding to sortilin, to Tg, or to both. Binding of Tg to sortilin was not affected by 
EDTA, indicating it is not calcium-dependent (Fig. 5f). As shown in Fig. 5g and h, 
binding was inhibited only at pH values ≤5.5, suggesting that probably the complex 
Tg-sortilin is stable in a relatively acidic environment with pH values ≥6.0.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
. 
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Figure 5  Binding of Tg to sortilin by surface plasmon resonance. a) T3 content of the Tg 
preparations used (rat Tg: rTg; human Tg: hTg; 5Tg: Tg purified from FRTL-5 cell 
supernatants); b) Binding of the three Tg preparations to immobilized sortilin; c) Dose-
dependence of hTg binding to sortilin; d) Inhibition of binding of the three Tg preparations to 
sortilin by neurotensin; e) Inhibition of hTg binding to sortilin by RAP; f) Lack of inhibition of 
binding of hTg to sortilin by EDTA; g-h) Effect of various pH values on binding of rTg (g) and 
hTg (h) to sortilin 
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Sortilin is not a Tg endocytic receptor 
In a first attempt to characterize the function of sortilin-Tg interactions in thyroid 
epithelial cells, we investigated whether sortilin mediates Tg binding to the cell 
membrane, as well as Tg uptake and/or degradation using: i) FRTL-5 cells, either 
untransfected or transiently transfected with a sortilin silencing RNA; ii) COS-7 cells 
either untransfected or transiently transfected with a sortilin cDNA or with the empty 
vector (pcDNA3); and iii) CHO cells stably transfected with a sortilin cDNA or with 
the empty vector (pcDNA3). In FRTL-5 cells, sortilin mRNA was found to decrease 
by ~86, ~60, and ~90 % at 24, 48 and 72 hours after transfection respectively, as 
observed by RT-PCR (Fig. 6a). In addition, as shown in Fig. 6b, a ~50% reduction of 
sortilin protein was observed by Western blotting (mean pixel density: cells 
transfected with scrambled sortilin RNA 124.9 pixels/cm2; cells transfected with 
silenced sortilin RNA 62.1 pixels/cm2) in cell extracts collected at 48h, the time at 
which the experiments reported below were performed. COS-7 cells were found to 
express sortilin protein upon transfection, as detected in cell extracts by Western 
blotting, although some was also found in the media, presumably reflecting release of 
sortilin by dead cells (Fig. 6c). An additional, faint anti-sortilin immunoreactive band 
migrating at ~170 kDa was seen in cell extracts, probably representing a constitutive, 
cross-reacting protein. Thus, a similar band was seen also in cells transfected with the 
empty vector. As shown in Fig. 6d, CHO cells were found to express sortilin protein 
upon transfection, as detected in cell extracts by Western blotting.   
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As shown in Fig. 7a and b, at 4°C biotin-labeled hTg bound to FRTL-5 cells and 
to a lesser extent also to COS-7 cells, whereas biotin-labeled BSA bound to a lesser 
extent than biotin-labeled hTg to both cell types. Thus, much greater amounts of BSA 
had to be used for an extent of binding similar to Tg to be reached. Tg bound to 
FRTL-5 cells to a similar extent regardless of whether cells were untransfected or 
sortilin had been silenced, and, in a similar fashion, it bound to COS-7 cells 
regardless of whether they were untransfected or transfected with sortilin. In 
experiments performed at 37°C (Fig. 7c) biotin-labeled hTg was found to be 
internalized by FRTL-5 cells in a time-dependent manner, to a much greater extent 
than by COS-7 cells, but, again, silencing of sortilin in FRTL-5 cells or transfection 
of sortilin in COS-7 cells did not affect uptake. Uptake of biotin-labeled BSA, used as 
a negative control, was negligible. The findings indicate that although Tg is capable 
of membrane binding and is internalized by both FRTL-5 and COS-7 cells to different 
extents, these processes are not mediated by sortilin, which is in keeping with the 
results reported above demonstrating that sortilin is not expressed on the thyrocyte 
membrane.  
Concerning binding and uptake at 37°C, similar results were obtained using 125I-
hTg. Thus, as shown in Fig. 7d, in FRTL-5 cells these processes were unaffected by 
sortilin silencing. In CHO cells, some degree of Tg binding and uptake was seen, 
which was lesser than in FRTL-5 cells, and unaffected by transfection with sortilin 
(Fig. 7d). The apparent differences in the amounts of 125I-hTg bound and internalized 
by FRTL-5 cells compared with experiments with biotin-labeled Tg can be attributed 
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to the much lower amounts of 125I-hTg applied to cells compared with biotin-labeled 
Tg.  In the same experiments, Tg degradation in both FRTL-5 and CHO cells was 
measured, and it was found not to be affected by sortilin silencing or by transfection 
with sortilin, respectively (Fig. 7d). Again, the findings indicate that sortilin is not 
involved in binding and uptake and also that it does not affect degradation of Tg. 
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Figure 6  a) Measurement of sortilin mRNA by RT-PCR in FRTL-5 cells transiently 
transfected with a sortilin silencing RNA or with a scrambled sortilin RNA, at different time 
points after transfection; b) Western blotting for sortilin in FRTL-5 cell extracts upon 
transfection with a sortilin silencing RNA or with a scrambled sortilin RNA; c) Western blotting  
for sortilin in extracts (lanes 1) and media (lanes 2) from COS-7 cells transiently transfected 
with a sortilin cDNA or with pcDNA3; d) Western blotting for sortilin in media (lanes 1) and 
extracts (lanes 2) from CHO cells stably transfected with a sortilin cDNA or with pcDNA3. 
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Figure 7  Lack of effect of sortilin on Tg binding, uptake and degradation. a-b) Binding of 
biotin-labeled hTg at 4°C, to FRTL-5 cells (a), using two different concentrations of hTg as 
indicated, and to COS-7 cells (b). Biotin-labeled BSA was used as a control; c) Uptake of 
biotin-labeled hTg at 37°C at various time points, by FRTL-5 and COS-7 cells. Biotin-labeled 
BSA was used as a control. Tg and BSA concentrations are indicated. d) Binding, uptake and 
degradation of 125I-hTg in FRTL-5 or CHO cells. The concentration is indicated. In all 
experiments FRTL-5 cells were used either untransfected, or 48 hours after transient 
transfection with a sortilin silencing RNA or with a scrambled sortilin RNA. COS-7 cells were 
used either untransfected or transiently transfected with a sortilin cDNA or with pcDNA3 for 48 
hours. CHO cells were used stably transfected with a sortilin cDNA or with pcDNA3. 
1
10
100
1000
10000
Tg 30 pM Tg 300 pM BSA 1.5 nM
Bo
un
d 
lig
an
ds
(pg
/µ
g 
of
 
pr
ot
ein
)
Untransfected
Scrambled Sortilin
Silenced Sortilin
a
c
0
5
10
15
20
25
30
15' 30' 60' 120' BSA 
In
te
rn
al
ize
d 
Tg
(pg
/µ
g 
of
 
pr
ot
ei
n)
FRTL-5 (Untransfected)
FRTL-5 (Scrambled Sortilin)
FRTL-5 (Silenced Sortilin)
Istogramma 4
COS-7 (Untransfected)
COS-7 (pcDNA3)
COS-7 (Sortilin)
Tg 300 pM 1.5 nM
120’
b
1
10
100
1000
10000
Tg 30 pM Tg 300 pM BSA 1.5 nM
Bo
u
n
d 
lig
an
ds
(pg
/µ
g 
of
 
pr
ot
ei
n
)
Untransfected
pcDNA3
Sortilin
Figure 7
0
1
2
3
4
Binding Uptake Degradation
 
Tg
(pg
/µ
g 
of
 
pr
ot
ei
n
)
FRTL-5 (Untransfected)
FRTL-5 (Scrambled Sortilin)
FRTL-5 (Silenced Sortilin)
Istogramma 4
CHO (pcDNA3)
CHO (Sortilin)
d
Tg 30 fM
Bo
un
d 
lig
an
ds
(pg
/µ
g 
of
 
pr
ot
ein
)
In
te
rn
al
ize
d 
Tg
(pg
/µ
g 
of
 
pr
ot
ei
n)
In
te
rn
al
ize
d 
Tg
(pg
/µ
g 
of
 
pr
ot
ei
n)
Bo
u
n
d 
lig
an
ds
(pg
/µ
g 
of
 
pr
ot
ei
n
)
Bo
u
n
d 
lig
an
ds
(pg
/µ
g 
of
 
pr
ot
ei
n
)
 
Tg
(pg
/µ
g 
of
 
pr
ot
ei
n
)
 - 57 -  
Sortilin does not bind to Tg in the biosynthetic pathway 
In view of the results reported above, we considered the possibility that Tg and 
sortilin may interact intracellularly, either during the Tg biosynthetic or endocytic 
pathway. To assess the first possibility, we investigated whether endogenous Tg binds 
to sortilin. For this purpose, we performed co-immunoprecipitation experiments upon 
protein cross-linking with a membrane permeable cross-linker. In FRTL-5 cells, an 
anti-sortilin antibody did not precipitate Tg (not shown), indicating that endogenous 
Tg and sortilin do not interact. In addition, sortilin and Tg did not co-localize in 
FRTL-5 cells, as found by immunofluorescence staining (Fig. 8a). Based on these 
findings, we concluded that newly synthesized, endogenous sortilin and Tg do not 
interact, implying that sortilin should not affect Tg secretion. The latter hypothesis 
was confirmed by experiments in which COS-7 cells were co-transfected with sortilin 
and Tg. Expression of sortilin and Tg upon transfection was demonstrated at similar 
levels when the two proteins were co-transfected or when either of them was co-
transfected with an unrelated gene (MC4) (Fig. 8b). The amount of Tg in the cell 
media did not differ between COS-7 cells co-transfected with Tg and sortilin and 
COS-7 cells co-transfected with Tg and MC4 (Fig. 8c-d). In spite of the apparent 
greater intensity of the Tg bands in COS-7 cells co-transfected with Tg and sortilin, a 
similar proportion of total Tg (Tg within extracts + Tg in the medium) was found in 
media of cells co-transfected with Tg and MC4 (41.2%) and of cells co-transfected 
with Tg and sortilin (40.4%).  
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Figure 8 Lack of sortilin-Tg interactions in the biosynthetic pathway. a) Immunofluorescence 
staining for sortilin and Tg in FRTL-5; b) Western blotting for Tg (upper panel) and sortilin 
(lower panel) in extracts from COS-7 cells co-transfected with sortilin and MC4, Tg and MC4 
or Tg and sortilin; c) Western blotting for sortilin in extracts and media from COS-7 cells co-
transfected with Tg and MC4 or Tg and sortilin; d) Pixel densities of the bands in Western 
blotting experiments. 
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Sortilin binds to Tg in the Tg endocytic pathway 
In view of the findings reported above, we considered the possibility that sortilin 
may bind to Tg following its endocytosis. We therefore investigated whether Tg and 
sortilin co-localize intracellularly upon Tg endocytosis, in uptake experiments with 
FRTL-5 cells performed at 37°C. Cells were incubated with biotin-labeled Tg and 
staining for biotin and sortilin was performed at various time points. As shown in Fig. 
9a, some internalized Tg molecules could be seen as early as 15 minutes after Tg was 
applied to cells. Staining increased progressively with time and at 2h Tg co-localized 
largely with sortilin in the perinuclear area. By immunoelectronmicroscopy with 
FRTL-5 cells on filters, gold-labeled Tg was found together with sortilin in large 
endocytic vesicles (Fig. 9b, left panel). In addition, vesicles containing gold-labeled 
Tg and sortilin were seen also extracellularly near the upper membrane (Fig. 9b, right 
panel), suggesting that, upon internalization, Tg may undergo recycling with its 
release together with sortilin from the upper membrane into the extracellular space.  
In support of the conclusion that sortilin binds to internalized Tg were results in co-
immunoprecipitation experiments. Thus, both in FRTL-5 cells and in COS-7 cells 
transfected with sortilin, an anti-sortilin antibody precipitated biotin-labeled Tg in cell 
extracts following 2h exposure of cells to the ligand at 37°C and chemical cross-
linking (Fig. 9c). 
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Figure 9  Sortilin-Tg interactions in the endocytic pathway. a) Immunofluorescence staining for sortilin and Tg 
in FRTL-5 cells, following incubation with biotin-labeled hTg at 37°C. At 2h Tg co-localizes largely with sortilin 
in the perinuclear area; b) Imunoelectronmicroscopy in FRTL-5 cells following incubation with gold-labeled Tg at 
37°C. Gold-labeled Tg (large particles) co-localizes with sortilin (small particles) within a large endosomal vesicle 
(left panel, arrows). Gold-labeled Tg and sortilin co-localize also extracellularly, near the apical membrane, within 
a vesicle (right panel, arrow); c) Co-immunoprecipitation of biotin-labeled Tg with an anti-sortilin antibody in 
extracts from FRTL-5 and COS-7 cells transfected with sortilin, following 2h exposure of cells to the ligand. 
0’ +15’ +30’ +60’ +120’
M
er
ge
B
io
tin
-
Tg
So
rt
ili
n
a
Figure 9
c
b
0’ 120’
COS-7 FRTL-5
0’ 120’
An
ti-
so
rti
lin
RI
gG
An
ti-
so
rti
lin
RI
gG
An
ti-
so
rti
lin
RI
gG
An
ti-
so
rti
lin
RI
gG
330 kDa
M
er
ge
B
io
tin
-
Tg
So
rt
ili
n
 - 61 -  
Sortilin-Tg interactions in the endocytic pathway result in Tg recycling 
Once we established that sortilin binds to internalized Tg, we investigated the 
intracellular fate of Tg upon sortilin binding. Based on results shown above and in 
Fig. 7, we excluded that sortilin is involved in lysosomal degradation of Tg, as this 
process was unaffected both by sortilin silencing in FRTL-5 cells and by transfection 
with sortilin in CHO cells. Therefore, we investigated the other two post-endocytic 
pathways of Tg, namely transcytosis and recycling. For transcytosis experiments, 
following transfection, cells were cultured in dual chambered devices and transcytosis 
assays were performed using unlabeled hTg as reported previously . As shown in Fig. 
10a, Tg transcytosis across FRTL-5 cells was unaffected by sortilin silencing, 
indicating that sortilin does not mediate this process. We then performed recycling 
assays, using unlabeled hTg in FRTL-5 and CHO cells. As shown In Fig. 10b, Tg 
recycling could be detected both in FRTL-5 and CHO cells. Silencing of sortilin in 
FRTL-5 cells resulted in a ~45% reduction of Tg recycling, which paralleled the 
reduction of sortilin expression shown above in Fig. 6a and b. In agreement with 
these findings, transfection of CHO cells with sortilin resulted in a ~50% increase of 
Tg recycling (Fig. 10b). 
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Figure 10 Sortilin-Tg interactions in the endocytic pathway result in Tg recycling. a) Transcytosis of 
unlabeled hTg across FRTL-5 cells either untransfected, or 48 hours after transient transfection with a 
sortilin silencing RNA or with a scrambled sortilin RNA; b) Recycling assays, using unlabeled hTg, in 
FRTL-5 cells (either untransfected, or 48 hours after transient transfection with a sortilin silencing 
RNA or with a scrambled sortilin RNA) and CHO cells (stably transfected with a sortilin cDNA or with 
pcDNA3).
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DISCUSSION 
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In the present study we provide evidence for a novel function of sortilin in the 
thyroid gland, namely recycling of the thyroid hormone precursor Tg after its 
endocytosis. Sortilin was originally identified as a RAP-binding neurotensin receptor 
in human brain membranes [5] and then found to be involved in various cell 
processes [22, 25, 51]. Being expressed within elements of the trafficking machinery, 
namely endosomes and Golgi, and in certain cells also on the cell membrane, sortilin 
has also the potential to participate in protein trafficking, as it occurs for some of its 
ligands [22, 25].  
Here we found that sortilin is expressed by thyroid epithelial cells, as shown in 
vivo as well as in cultured thyroid cells. By immunostaining techniques, expression of 
sortilin was found to be concentrated mainly intracellularly, as observed using various 
techniques, whereas sortilin was not seen on the cell membrane. Expression of sortilin 
in thyroid epithelial cells was found to be TSH-dependent, which is an indirect 
evidence of a possible thyroid-specific function of sortilin, as it occurs for virtually all 
proteins involved in thyroid function [101]. Thus, sortilin expression in mice 
increased dramatically when they were treated with methimazole and perchlorate, as a 
mean to enhance TSH levels [92]. In addition, expression of sortilin in cultured 
thyroid cells was found to be up-regulated by exogenous TSH in a time-, dose-
dependent and saturable manner. 
Sortilin was found to be capable of interacting with Tg with high affinity. Thus, 
three Tg preparations bound to immobilized sortilin with affinities that paralleled 
their hormone content, suggesting that sortilin binds especially to hormonogenic Tg 
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molecules. Interestingly, binding was found to be relatively resistant to low pH, but 
not to be calcium-dependent. In addition, binding was highly specific, as 
demonstrated by its dose-dependence, by the inhibition with a specific sortilin ligand 
(neurotensin) and by a ligand common to both sortilin and Tg (RAP), by the absence 
of inhibition by control proteins, and by the absence of Tg binding to another member 
of the Vps10p family, namely SorCS3.  
We failed to demonstrate that in thyroid cells Tg binds to sortilin on the cell 
membrane, as expected from the lack of expression of sortilin at that level. In 
addition, we failed to demonstrate that sortilin is involved in Tg endocytosis. The 
finding that Tg-sortilin interactions are relatively resistant to low pH coupled with the 
knowledge that in thyroid cells sortilin is exclusively expressed intracellularly, led us 
to the hypothesis that sortilin-Tg interactions may occur at that level. The possibility 
that sortilin and Tg interact during the biosynthetic pathway was excluded by the 
following findings. First, endogenous Tg synthesized by FRTL-5 cells was not 
precipitated by anti-sortilin antibodies. Second, endogenous Tg and sortilin did not 
co-localize in FRTL-5 cells. Third, Tg secretion into the cell medium of COS-7 cells 
transfected with Tg was not affected by co-transfection with sortilin.  
Based on these results, we investigated whether Tg-sortilin interactions may occur 
upon endocytosis of Tg, leading to targeting of Tg to either lysosomal degradation, 
transcytosis or recycling. The finding that Tg co-localizes with sortilin upon its 
endocytosis suggested that this was likely the case. Thus, following incubation of 
FRTL-5 cells with exogenous Tg, endocytosed Tg co-localized with sortilin in the 
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perinuclear area. In addition, by immunoelectronmicroscopy internalized Tg was seen 
in large endocytic vesicles where also sortilin was present. We investigated the fate of 
internalized Tg using several experimental approaches. Lysosomal degradation of Tg, 
a pathway that leads to the release of thyroid hormones upon fluid phase endocytosis 
of hormonogenic Tg molecules at the apical membrane of thyroid epithelial cells [73], 
was apparently not affected by sortilin. Thus, degradation of radiolabeled Tg was 
unchanged by sortilin silencing in FRTL-5 cells or by transfection with sortilin in 
CHO cells. Transcytosis, namely transport of Tg across the thyroid epithelial layer 
with subsequent release into the bloodstream, which occurs following megalin-
mediated endocytosis of Tg [83, 84, 88], was also unaffected by sortilin. Thus, similar 
amounts of exogenous Tg were transcytosed by FRTL-5 cells regardless of whether 
sortilin had been silenced. 
The intracellular interaction of Tg with sortilin most likely results in recycling of 
Tg. Thus, when cells were incubated with exogenous Tg, release of Tg into the 
medium following its endocytosis was reduced by sortilin silencing in FRTL-5 cells 
and increased by transfection with sortilin in CHO cells. In addition, following 
incubation of FRTL-5 on filters with gold labeled Tg, vesicles containing sortilin and 
Tg were found extracellularly, very close to the apical membrane.  
Recycling of Tg following endocytosis was originally described by Kostrouch 
[80]. The process seems to involve Tg molecules with a poor degree of glycosilation 
that upon endocytosis are re-directed to the Golgi for further glycosilation and then 
re-secreted into the lumen of thyroid follicles. Recycling is thought to occur after 
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receptor-mediated endocytosis of Tg, although the responsible receptor is yet to be 
identified with certainty [72]. The finding that sortilin affects Tg recycling suggests 
that sortilin may provide a targeting signal leading to this pathway following Tg 
endocytosis. Whether this ultimately results in Tg glycosilation within the Golgi was 
not established here and will be the subject of additional studies.  
The functional impact of Tg recycling via sortilin in the short term seems to be 
negligible. Thus, the fact that Tg degradation was not affected by sortilin indicates 
that, at least with the experimental conditions applied here, whether Tg is recycled or 
not does not affect hormone release. Nevertheless, it is possible that recycling may 
have an effect in the long term, an issue that can be studied only in animal models. In 
this regard, the ideal model would be sortilin KO mice, which development and 
investigations will be the subject of further  studies. 
Our findings provide a novel pathway of Tg trafficking although its functional impact 
remains to be established. In addition, we provide evidence for a novel function of 
sortilin in the thyroid gland, in addition to the roles that have been identified for this 
protein in other tissues [25]. 
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